What question did this study set out to answer?

To assess whether intravenous tenecteplase is associated with improved 90-day clinical outcomes compared with standard medical treatment in patients with minor acute ischemic stroke caused by anterior-circulation medium-vessel occlusion.

August 31, 2026Frontiers in NeuroscienceOpen Access

Tenecteplase versus standard medical treatment for minor stroke due to anterior-circulation medium-vessel occlusion: a multicenter observational study

View Full Paper

Ask AI

Bookmark

To assess whether intravenous tenecteplase is associated with improved 90-day clinical outcomes compared with standard medical treatment in patients with minor acute ischemic stroke caused by anterior-circulation medium-vessel occlusion.
Multicenter, retrospective observational study evaluating consecutive patients (N=216) with minor acute ischemic stroke (NIHSS <6) and imaging-confirmed anterior-circulation medium-vessel occlusion.
Patients were classified into intravenous tenecteplase (n=64) or standard medical treatment without thrombolysis (n=152), using inverse probability of treatment weighting (IPTW) to balance baseline characteristics.
Tenecteplase was associated with a higher rate of excellent functional outcome (mRS 0–1) at 90 days compared with standard medical treatment after IPTW adjustment (70.3% vs. 53.3%; aOR, 2.07; 95% CI, 1.11–3.87).
Patients receiving tenecteplase achieved higher rates of 90-day functional independence (mRS 0–2: 81.3% vs. 64.5%; aOR, 2.39; 95% CI, 1.18–4.87).
No statistically significant differences occurred between tenecteplase and standard treatment for hemorrhagic transformation (5.2% vs. 7.0%) or symptomatic intracranial hemorrhage (3.4% vs. 4.3%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study demonstrates improved 90-day recovery with tenecteplase over standard medical treatment in minor medium-vessel stroke, highlighting a viable thrombolytic option.

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/6aa941ebe4c74ea0188793b1 https://doi.org/10.3389/fnins.2026.1931392

View Full Paper

Ask AI

Bookmark

Implication

Observational study demonstrates improved 90-day recovery with tenecteplase over standard medical treatment in minor medium-vessel stroke, highlighting a viable thrombolytic option.

Tenecteplase versus standard medical treatment for minor stroke due to anterior-circulation medium-vessel occlusion: a multicenter observational study

Key Points

Discussion

Implication

Cite This Study

Tenecteplase versus standard medical treatment for minor stroke due to anterior-circulation medium-vessel occlusion: a multicenter observational study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider